GlobeNewsWire
16 Jun 2026, 11:32 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Clearmind Medicine has completed dosing for all 24 participants in Part A of its Phase I/II clinical trial for CMND-100 in treating Alcohol Use Disorder. — Completion of a primary trial phase is a critical milestone that reduces execution risk and moves the candidate closer to efficacy data.
+0.40Interim results from the first three cohorts of the trial indicate a strong safety profile for CMND-100. — Safety is the primary goal of Phase I trials; a positive safety profile prevents early-stage failure and allows the trial to proceed to higher doses or efficacy testing.
+0.30Which stocks this story touches
The company successfully completed dosing for Part A of its Phase I/II clinical trial with a strong safety profile.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
14h ago
